Patients with RA were divided into two random groups, that is, treated with a placebo or a humanized IgG1 monoclonal antibody (ASK8007) directed to the cryptic site of OPN and inhibiting both RGD- and α9β1 integrin-dependent cell binding to human OPN [180, 181]. The gene discussed is SPP1; the disease is rheumatoid arthritis.